Cullinan Oncology Inc is a biotechnology business based in the US. Cullinan Oncology shares (CGEM) are listed on the NASDAQ and all prices are listed in US Dollars. Cullinan Oncology employs 28 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Cullinan Oncology
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CGEM – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Cullinan Oncology stock price (NASDAQ: CGEM)Use our graph to track the performance of CGEM stocks over time.
Cullinan Oncology shares at a glance
|Latest market close||$21.89|
|52-week range||$21.97 - $59.85|
|50-day moving average||$25.68|
|200-day moving average||$28.43|
|Wall St. target price||$51.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.54|
Buy Cullinan Oncology shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Cullinan Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cullinan Oncology price performance over time
|1 week (2021-10-15)||-12.44%|
|1 month (2021-09-22)||-2.97%|
|3 months (2021-07-22)||-16.23%|
|6 months (2021-04-22)||-32.60%|
|1 year (2020-10-18)||N/A|
|2 years (2019-10-18)||N/A|
|3 years (2018-10-18)||N/A|
|5 years (2016-10-18)||N/A|
Cullinan Oncology financials
|Revenue TTM||$18.9 million|
|Gross profit TTM||$0|
|Return on assets TTM||-13.7%|
|Return on equity TTM||-19.89%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
Shorting Cullinan Oncology shares
There are currently 2.6 million Cullinan Oncology shares held short by investors – that's known as Cullinan Oncology's "short interest". This figure is 42.9% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting Cullinan Oncology shares can be evaluated.
Cullinan Oncology's "short interest ratio" (SIR)
Cullinan Oncology's "short interest ratio" (SIR) is the quantity of Cullinan Oncology shares currently shorted divided by the average quantity of Cullinan Oncology shares traded daily (recently around 335800.51746442). Cullinan Oncology's SIR currently stands at 7.73. In other words for every 100,000 Cullinan Oncology shares traded daily on the market, roughly 7730 shares are currently held short.
To gain some more context, you can compare Cullinan Oncology's short interest ratio against those of similar companies.
However Cullinan Oncology's short interest can also be evaluated against the total number of Cullinan Oncology shares, or, against the total number of tradable Cullinan Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cullinan Oncology's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Cullinan Oncology shares in existence, roughly 60 shares are currently held short) or 0.1113% of the tradable shares (for every 100,000 tradable Cullinan Oncology shares, roughly 111 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cullinan Oncology.
Find out more about how you can short Cullinan Oncology stock.
Cullinan Oncology share dividends
We're not expecting Cullinan Oncology to pay a dividend over the next 12 months.
You may also wish to consider:
- Amgen (AMGN.US) (3.25% forward annual dividend yield)
Have Cullinan Oncology's shares ever split?
Cullinan Oncology's shares were split on a 2:1 basis on 30 August 2009. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cullinan Oncology shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cullinan Oncology shares which in turn could have impacted Cullinan Oncology's share price.
Cullinan Oncology overview
Cullinan Management, Inc. , a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc.
Cullinan Oncology in the news
46 Biggest Movers From Yesterday
34 Stocks Moving In Monday's Mid-Day Session
Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer
Frequently asked questionsWhat percentage of Cullinan Oncology is owned by insiders or institutions?
Currently 18.378% of Cullinan Oncology shares are held by insiders and 74.213% by institutions. How many people work for Cullinan Oncology?
Latest data suggests 28 work at Cullinan Oncology. When does the fiscal year end for Cullinan Oncology?
Cullinan Oncology's fiscal year ends in December. Where is Cullinan Oncology based?
Cullinan Oncology's address is: One Main Street, Cambridge, MA, United States, 02142 What is Cullinan Oncology's ISIN number?
Cullinan Oncology's international securities identification number is: US2300311063
More guides on Finder
How to buy ProShares Bitcoin Strategy ETF (BITO)
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
How to buy Progressive Care stock when it goes public
Everything we know about the Progressive Care IPO, plus information on how to buy in.
How to buy Desert Peak Minerals (DPM) stock when it goes public
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
How to buy Vaxxinity (VAXX) stock when it goes public
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
How to buy Entrada Therapeutics (TRDA) stock when it goes public
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Ask an Expert